1. Home
  2. CRBU vs EVG Comparison

CRBU vs EVG Comparison

Compare CRBU & EVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

N/A

Current Price

$1.76

Market Cap

145.8M

Sector

Health Care

ML Signal

N/A

Logo Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

EVG

Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

N/A

Current Price

$10.69

Market Cap

144.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CRBU
EVG
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
145.8M
144.1M
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
CRBU
EVG
Price
$1.76
$10.69
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$10.75
N/A
AVG Volume (30 Days)
1.0M
44.9K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
3.64
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.63
N/A
Revenue Next Year
$10.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.38
$10.40
52 Week High
$3.53
$11.45

Technical Indicators

Market Signals
Indicator
CRBU
EVG
Relative Strength Index (RSI) 54.94 45.53
Support Level $1.40 $10.47
Resistance Level $1.70 $10.92
Average True Range (ATR) 0.07 0.13
MACD 0.01 -0.01
Stochastic Oscillator 85.00 20.59

Price Performance

Historical Comparison
CRBU
EVG

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.

Share on Social Networks: